Hess G, Eyre TA, Jen MH, Zhang J, et al. A matching-adjusted indirect comparison of survival outcomes with pirtobrutinib (BRUIN) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma previously treated with a covalent Bruton tyrosine kinase inhibitor. Br J Haematol 2025 Nov 17. doi: 10.1111/bjh.70237.
PMID: 41251068